Background-Evidence-based guidelines recommend that all newly diagnosed colon cancers be screened for Lynch syndrome (LS). Best practices for implementing universal tumor screening have not been extensively studied.
INTRODUCTION
Colorectal cancer (CRC) is the second leading cause of cancer death in the United States. 1 Approximately 2-3% of CRC cases are attributable to a genetic predisposition associated with germline mutations in mismatch repair (MMR) genes, 2 an autosomal dominant condition known as Lynch syndrome (LS). LS is the most common form of hereditary CRC 3 and can be recognized by either family history criteria or by characteristic molecular profile in the tumor. Based on evidence that universal tumor testing would save lives, 4 , 5 several national groups have recommended all CRC tumors regardless of age or family history be screened for LS using laboratory assays.
Two lab-based assays are used today to screen for LS -microsatellite instability (MSI) and immunohistochemistry (IHC). Defects in the MMR pathway cause errors in DNA replication, known as microsatellite instability, and can be seen in in about 15% of sporadic colon tumors and in 85% of tumors in patients with LS. 7 MSI testing is performed on the DNA extracted from the tumor, with a sensitivity and specificity to detect germline MMR mutations of 85%, and 90%, respectively. 8 -12 IHC detects under-expression of proteins encoded by MMR genes in the MMR pathway. 13 , 14 However, because not all germline mutations result in absent MMR proteins in the tumor, 11 the sensitivity of IHC testing for identifying germline mutations is about 83%, and specificity is about 90% . 4 Thus, MSI and IHC testing are lab based LS screening tests because they cannot distinguish between somatic versus germline causes of MSI in tumors.
While clinical criteria for screening Lynch syndrome exists (e.g., Bethesda or Amsterdam criteria), more than half of patients meeting clinical criteria do not receive screening. 15 , 16 Seventy-one percent of the 41 NCI-Comprehensive Cancer Centers across the U.S. conducted lab-based universal LS screening in 2009, yet only 15% of community hospital cancer programs regularly screened for LS using tumor testing methods. 17 Furthermore, using data from a 2004-2009 study of seven Health Maintenance Organizations found that none were performing universal LS screening, and fewer than 4% of colon cancer patients were tested for LS. 18 Although uptake of universal LS screening is less than optimal, we understand little about why. Most research on LS screening implementation come from one type of stakeholder (e.g. physician or genetic counselor) or focuses on high-risk or research populations; data from a broader organizational perspective or population are more limited. 19 Research has shed light on some possible barriers: Physician interviews at mostly university-affiliated medical centers have raised questions about the ability to follow up with at-risk patients, and concerns about consent, cost effectiveness, and ethical issues regarding informing relatives 20 about test results. Hall 21 discusses concerns about patient psychosocial burdens and gaps in clinical expertise, while a national survey of genetic counselors identified implementation barriers regarding variability in returning results, cost uncertainties, and lack of clinical/ leadership or buy-in. 22 To better understand the initial factors involved in implementing universal LS screening in an integrated health care system, we conducted interviews with health plan and clinical stakeholders in a large health maintenance organization (HMO) during the early phase of their implementation deliberations. Specifically, we interviewed individuals to gather a range of perspectives from health plan leaders/managers, and from frontline staff to uncover early challenges and facilitators to the successful implementation of LS screening. The results are the focus of this report.
MATERIALS AND METHODS

Background and Study Site
Kaiser Permanente Northwest (KPNW) is an integrated HMO that serves approximately 490,000 health plan members in the Portland, Oregon metropolitan area. KPNW comprises three primary and inter-related organizational structures: 1) a private corporation of medical doctors that contract to provide care to KPNW health plan members; 2) the KPNW health plan; and 3) related KP-owned and managed hospitals and clinics. All patient care is documented through an electronic medical record (EMR). Prior to this study, we estimated that only 5% of CRCs were screened for LS in this health system, with KPNW relying on provider or self-referrals to the medical genetics department for screening based on clinical criteria.
Recruitment and Participants
We recruited leaders (senior level and managers) and staff (frontline) representing both the medical and health plan sides of the organization for qualitative interviews. We recruited participants from a range of departments including: pathology, oncology, medical genetics, gynecology, surgery, laboratory services, and administration. We used a purposeful, rolebased sample, 23 recruiting participants either due to their role, their past experience with LS screening, or because colleagues or interviewees identified them as having an important perspective. Participants were recruited via email; we followed up with telephone or email for those expressing interest. We continued to recruit until no "new" potential interview participants were identified to us. Interviews occurred during August 2012-April 2013, were conducted over the phone or in person, and lasted 45-60 minutes.
Data Collection Methods
Qualitative methods are effective strategies for analyzing complex social phenomena, 23 , 24 and can reveal information unanticipated by researchers. 25 -27 Thus, the research team designed an open-ended interview guide based on prior experience and a literature review. 25 -27 We conducted interviews in two phases. We first interviewed staff engaged with the day-to-day responsibilities of LS screening (e.g., genetic counselors, pathologists), asking about current role, perceived impact on department workflows and staff, concerns about implementing universal screening, and factors that hinder or facilitate screening.
Interviewees from this first round emphasized the importance of being thorough in including all potential stakeholders early on who may have an opinion about or role in universal LS implementation. Given this feedback, in our second round of interviews we solicited input from health plan leaders or managers, such as department chiefs and other decision-makers in key department areas. We broadened the scope of our questions beyond daily implementation details and focused on the potential to establish universal LS screening as an organizational standard of care. We asked about the perceived value of universal screening, what factors influence practice change, organizational barriers and facilitators, and who might serve as organizational champions of universal screening. All interviews were conducted by a trained qualitative interviewer (JD), and were audio-recorded and transcribed verbatim. Interview procedures and materials were approved by the Institutional Review Board at the Kaiser Permanente Center for Health Research.
Conceptual Framework and Analysis Process
We employed the Practical Robust Implementation and Sustainability Model (PRISM) 28 to help orient our analysis of the interview data. PRISM is a concrete, conceptual framework to help researchers or organizations identify and understand the factors potentially needed to foster implementation and maintenance of a health care program/intervention. PRISM has several inter-relating core domains: (1) the program (intervention) viewed from both the organization and patient perspective; 2) the recipients (both organization and patient characteristics); 3) the external environment (e.g. regulations, competition, etc.); and 4) the organizations' implementation and sustainability infrastructure. Figure 1 shows these domains and describes related elements that might be considered within each. 28 A unique aspect of PRISM is that the organizational perspectives and characteristics are considered at three different levels: among senior leaders, mid-level managers, and frontline workers. The framework suggests documenting and defining key factors of internal (organizational) and external (environment) influence. Given that our interviews were with a range organizational staff, and did not directly include patients, we broadly reviewed our interview data from the point of view of the following 
RESULTS
Of the 15 participants recruited, we completed 14 interviews (one declined)-seven with frontline staff and seven with leaders/managers. Overall, we interviewed 8 female and 6 male participants, with almost half (43%) having over 10 years of experience with the organization (Table 1 ). Here we report on external (environment) and internal (organizational) factors that either facilitated implementation of universal LS screening (Table 2 ) or presented challenges (Table 3) .
External (Environment) Facilitators
Participants described a national trend pushing organizations toward universal LS screening, shaped by literature on the benefits of LS screening, and recognition that medicine is moving toward genetic screening as a standard. Awareness of other health care organizations having implemented universal LS screening also contributed to participants' sense of a national movement. Participants described a "shift" in views among peers that universal LS screening is a service long overdue which should be implemented. While both staff and leaders cited the national trend and the influence of others, leaders cited these more often.
Both staff and leaders cited potential benefits to patients and their family members as an important external factor. A majority of leaders believed that LS screening offers equal benefit to both the patient and his/her family members. Staff and leaders strongly believed that a universal LS screening program could save the lives of the primary patient and their family members by helping to catch related cancers early, and directly influence current and follow-up care.
Internal (Organizational) Facilitators
Staff and leaders also cited an overarching organizational advocacy for universal LS screening as a strong driver to implementation. Half or more of both groups believed that universal LS screening is a worthwhile goal and the "right thing to do" for patients. They cited awareness of colleagues within their own department or in other departments having a similar supportive stance. This advocacy was bolstered by a belief that the confirmation of a diagnosis from screening adds value to patient care by guiding surgery, follow-up tests, and surveillance. A majority of leaders also recognized that implementing LS screening as a standard practice would align with the organization's overall goals to improve CRC screening and treatment.
Respondents told us that positive inter-department relationships and experienced staff were important facilitators. A majority of both staff and leaders cited a history of innovative, flexible, and collaborative communication across the involved departments. Additionally, respondents viewed the staff of participating departments (pathology and genetics) as skilled and experienced, having already designed and implemented workflows for other universal genetic screening tests (such as Her-2 neu testing of breast cancers) that could be modified for LS screening. Respondents said the combination of historical collaboration, communication, and experienced staff gave them confidence in the organization's ability to design a universal LS program.
Participants also described organizational resources, such as testing equipment, and prior experience with other genetic screening programs that demonstrated minimal negative impact on resources and staff time. Leaders expressed that potential cost-savings was a facilitator, and most believed the costs of setting up and maintaining a universal LS screening program would be outweighed by eventual cost savings from preventing patients from moving into advanced disease.
External (Environment) Challenges
Overall lack of awareness about what is normative in the field of CRC screening came up specifically with leaders as a hindrance. They expressed a belief that the United States is generally "behind the times" in prevention and screening options for CRC compared to other countries. More than half of the leaders felt the public lacked awareness about CRC screening in general and that there was even less public understanding about LS screening. A majority of leaders expressed not knowing who else was implementing universal LS screening or what national recommendations, if any, existed to guide implementation efforts.
Both leaders and staff cited the perceived lack of clarity and agreement related to LS screening guidelines as an implementation barrier. Leaders expressed that the national criteria recommendations were still too variable to concretely guide practice change. For example, more than half of those interviewed expressed a sense of uncertainty regarding how to best transition from the current, family history-based criteria (Amsterdam or Bethesda) into a universal screening program. Participants perceived variability in recommended guidelines, which added to uncertainty about how to design and implement a program. Participants were unclear on the most appropriate criteria for identifying patients, or which screening test (MSI, IHC, or both) should be chosen.
Interviewees less frequently described patient and family member considerations as external barriers; primarily citing that family members who are not a part of the same health plan would be difficult to track and contact post-diagnosis. A few respondents also mentioned concerns about whether a consenting process would be needed for tumor screening, and if so, whether the need for consent could create a barrier. Some leaders expressed concern that patients may decline lab testing due to fear of health insurance discrimination that could follow.
Internal (Organizational) Challenges
Participants described several historical organizational barriers. LS screening has been perceived as a difficult process to set up because it involves multiple, complex factors and related decisions. Leaders, in particular, articulated this as an ongoing barrier. Factors related to the complexity barrier include: 1) concern there would not be sufficient time within the context of already heavy workloads for needed staff to navigate through the decision points in such a process; 2) lack of a clear champion to lead such an effort and obtain commitment and consensus across departments; and 3) uncertainty as to which department(s) should "own" the screening program.
Participants identified department constraints on universal LS screening. A majority described how departments involved with implementing LS screening would be resistant to any perceived increase in workload without an equivalent match in staffing. Additionally, interviewees described how this sensitivity to increases in workload, along with budget constraints for involved departments, amplified some departments' resistance to "own" the program.
Interviewees also identified resource and cost uncertainties as barriers, including recognition that genetic screening services can be expensive to provide, and that these services may not generate income. Participants described how challenging it is to determine whether cost savings could be realized if a program is implemented because some benefits may be for family members who are not health plan members. This is further complicated by uncertainties about how to fund the screening program, including uncertainty about which department budgets might help pay for it. These cost barriers were more often described by leaders.
Key Implementation and Infrastructure Factors
We also asked participants in an open-ended fashion for their perspective on what would be needed for developing, implementing, and sustaining a successful universal LS screening program for their organization. Analysis of participant responses revealed nine key considerations: (1) establishing/ standardizing roles, tasks, and workflows; (2) developing electronic structures for ordering and tracking results; (3) finding champions and involving key departments; (4) determining the laboratory location and needs for processing the screening test; (5) conducting a business case analysis; (6) establishing partnerships and best practices with other organizations that have implemented universal LS screening; (7) selecting the appropriate screening method (MSI, IHC or both) for the organization; (8) conducting an awareness/education campaign for all staff and patients; and (9) determining which department(s) within the organization would own and manage the screening program. The details of these key implementation and infrastructure factors are presented in Table 4 in the order of how often they were mentioned by our interviewees.
DISCUSSION
Our interviews demonstrated that many external and internal factors influence an organization's decision to implement universal LS tumor screening as a part of standard care.
Respondents revealed nine critical, and often inter-related, organizational decision-points that reflect elements found in the core domains of PRISM. The top three considerations from our interviewees centered broadly on establishing support and developing infrastructure, and encompass such PRISM elements as: management/leader support; clinical leadership; shared goals and cooperation; coordination across departments; staffing; burden; systems and training; data and decision support; adaptable protocols and procedures; and having a dedicated team. For example, our respondents talked a great deal about the importance of creating standardized roles and task expectations, and having clear communication and documentation workflows across involved functions (e.g., pathology, genetics). As vital to that effort, our interviewees described the need to develop and build EMR structures to support staff in electronically placing and tracking orders and related results. Deciding who has ultimate responsibility for program execution and monitoring was further cited as integral to any implementation effort, and for establishing clear roles and task expectations to promote ongoing sustainability.
Determining the laboratory (external vs. internal) for processing the chosen screening test was also a major focus of discussion and highlights from the PRISM perspective the interrelationship between elements of readiness, strength of the evidence base, observability of results, and infrastructure needs. While knowledge and understanding of the selected screening method (MSI or IHC) may help to determine the laboratory decision for some organizations, our respondents suggested considering staffing expertise, ease of integration into existing structures, and accuracy/timeliness of results as additional considerations. A study by Hampel et al, 31 showed that IHC and MSI are similar in having high sensitivity to detect LS. Given this, issues of staffing expertise and EMR/workflow integration may prove to be more germane implementation infrascture considerations.
Stakeholder buy-in, engagement, and involvement were described as critical. Neglecting these considerations has been found to be a barrier for others seeking universal LS screening. 22 As suggested by our interviewees, identifying champions for universal LS screening from key departments, involving them in educating their colleagues and integrating their input early into planning and decision-making, is vital to program implementation success.
However, even with strong organizational support and participation, factors from the external environment may create potential challenges to implementation. Our respondents described several potential barriers from the external environment, including their concerns about unclear universal screening guidelines, lack of knowledge about what other institutions were doing, and tracking family members across different health-plans. Comments about lack of clear guidelines highlights stakeholders' concerns with the Bethesda and Amsterdam criteria, and emphasizes the potential implementation impact of the PRISM elements pertaining to strength of the evidence, competition, and the regulatory environment. For LS screening, recommendations from two national workgroups 5 , 6 may help address these uncertainties, since they recommend screening for all colorectal cancer patients. In 2009, the Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group recommended that all CRC tumors be screened for LS using laboratory assays. Further, in 2013, the National Comprehensive Cancer Network (NCCN) published practice guidelines for colorectal cancer that included testing all colorectal tumors. Additionally, stakeholder concerns about tracking and follow up with family members belonging to different health plans may become less of an issue as more health plans institute universal LS screening. In the future, health plans will need to acknowledge the public health benefit of population-based LS screening. The ability to electronically view, request, and track results across organizations will help to coordinate this effort A primary organizational (internal) barrier discussed by our interviewees centered on needed resources and potential costs to implement a universal LS screening program. Participants viewed understanding and identifying costs and potential resources as a complex, timeconsuming process. Several published cost effectiveness studies may help address these concerns. One study modeled a hypothetical cohort of 150,000 newly diagnosed CRC patients and found universal MSI and IHC screening to be cost-effective, with IHC having the lowest cost per life year saved. 32 Another utilized Markov modeling of newly diagnosed CRC patients and also found IHC the most cost-effective approach. 33 The number of relatives tested was the key driver in cost-effectiveness. Furthermore, Gudgeon et al based their model on a cohort of CRC patients from their health care system, reporting MSI as substantially less cost-effective than IHC.
34
Our study had limitations; our small sample size (n=14) may limit the generalizability of our findings to other settings. Our selection of participants by convenience and role may have led to selection bias, while social desirability bias (participants telling us what they think we want to hear) may have limited accuracy. Conducting the interviews in two phases may have contributed to inconsistencies in interpretation of the data given we did not go back and reinterview frontline staff with some of the additional questions that were added to the interview guide for leaders. Additionally, while we cannot discern whether stakeholders' responses represent the feelings of non-interviewed staff or the perspectives of health plan leaders/managers across the system, responses were sufficiently consistent that we could identify themes and patterns. Our findings are also limited to the timeframe in which interviews were conducted during the very initial stages of considering universal LS screening, thus they focus primarily on early implementation barriers and facilitators. Furthermore, the interviews were conducted as part of a study on the implementation of universal LS screening within this organization so awareness of the study could have had an impact on responses. Thus, the organization reflects a state where there is at least some institutional buy-in to considering a universal LS screening program. While the details of some organizational and infrastructure considerations under some themes may be unique to the organization under study and therefore less generalizable, the overarching themes may still be useful guideposts. Finally, the patient perspective is limited to the interpretations of the organizational staff interviewed, and does not reflect opinions derived directly from patients.
We employed several strategies to improve the thematic trustworthiness of our data, 23 including using a trained interviewer and interview guide to improve consistency; obtaining a range of viewpoints representing different roles and functions within the organization; using a formal, team-based approach to analysis that included both an "insider" and "outsider" review of the data; engaging in a two-step analysis process that incorporated both standard qualitative open-coding techniques as well as guidance from a conceptual framework; and reviewing our findings with study staff and advisory board members to challenge and improve consistency of interpretation. Future research may explore postanalytical issues after tumor testing, including workflows, communication, and best practices between genetic counselors, patients, and related family members. Additionally, given that we did not interview patients or their family members in this stage, researchers may want to explore LS screening from a family perspective to help create a paradigm shift that would allow realization of the full potential of LS screening as a population-based approach.
Identifying early challenges and key infrastructure factors may help similar organizations incorporate universal LS screening. We observed widespread support across stakeholder groups in the health system we studied. Successful implementation, however, will require ongoing interdepartmental collaboration and communication, patient and provider/staff education, and significant infrastructure and resource support, particularly for laboratory processing and electronic ordering and tracking. Table 1 Characteristics of Interview Participants (n=14) Table 2 External and Internal Facilitators to Implementing Universal LS Screening: Staff and Leader Perspectives (n=14)
Gender
Facilitators from the external environment Facilitators within the internal organization National trend Overarching organizational belief/advocacy
• Science / literature support moving in the direction of universal LS screening a
• LS screening as a standard practice is aligned with the organization's goals and metrics to improve CRC screening and prevention a
• Recognition medicine is moving in the direction of more genetic screening and services covered within the context of standard care a
• Strong advocacy across multiple departments and roles that universal LS screening is a worthwhile goal and the "right thing to do" b
Illustrative quote: "There is more and more literature coming out that suggests the incidence of this [LS] is much higher than people thought originally... so I think through an aggressive identification and surveillance process, we would do better for our patients." (Leader)
• Belief that knowledge and confirmation of a diagnosis from universal LS screening adds value to patient care by guiding surgery, follow-up tests, and surveillance activities b • Shift among colleagues/peers that universal LS screening is an overdue services that should be implemented a
• Experienced and skilled staff that have already designed and put into place workflows for other genetic screening tests and CRC tests/labs that can be modified appropriately for LS screening b
Illustrative quote: "I know that the thinking among my colleagues now is beginning to change -and I think if it's something that is worthwhile in helping patient care, then we are willing to consider it." (Leader)
Illustrative quote: "I think a main thing is a good relationship between pathology and other departments...They are a vibrant and active department that I think is flexible. And they do a lot of innovation, and I think this would be another example of them being in the forefront of doing the right thing." (Leader)
Patient/family member benefit and receptivity Available resources /potential costs
• Belief there is equal benefit from universal LS screening for both the index patient and their family members a
• Currently have some equipment for IHC testing, and a committee in place to study costissues related to setting up universal LS screening
• Strong belief universal LS screening will help catch CRC early, save lives, and directly influence care and follow-up procedures for the patient and family members b
• Prior experience with other implemented genetic screening programs has demonstrated minimal negative impact on various department resources/staff time Illustrative quotes: "I think it has equal importance -it's for the patient's own management and for pre-symptomatic testing of their relatives." (Leader)
• Belief the impact on staff time and resources will be minimal if the work of universal LS screening is spread equally and appropriately across impacted departments "I've had several patients' that have tested positive for MSI testing... it certainly portends further screening for their other colorectal health as well as their breast health, but then also for their families as well." (Staff)
• Belief that the upfront costs of setting up a LS screening program will be outweighed by the savings to the organization from avoidance of advanced disease state (Leader only)
Illustrative quote: "We'd also save the organization money and resources in the long run because, hopefully, we are preventing cancers and detecting them earlier...so that is a real benefit and it's the right thing to do." (Leader) • Lack of awareness about the importance and benefit of universal LS screening by some physicians and specialist
• Not all departments potentially involved place the same level of value on genetic testing Illustrative quote: "Everybody is maxed out... And so, I just think there might be some resistance. I think it's a fantastic universal substitute for patients and their families, but I think adding that burden to a department without increasing FTE would be difficult." (Staff)
Patient/family member considerations Needed resources/cost uncertainties
• Concern family member's not on index patient's health plan cannot be followed up with easily post diagnosis
• Genetic services not viewed as a revenue generating for the organizations a
• Questions exist as to whether patient consent is needed or not, and if so how to best establish this process
• Determining return on investment or cost savings to organization is challenging when some of the perceived benefits of the program may be for family members who are not necessarily health plan members a
• Patients may be resistant to LS screening and decline it due to fear of health insurance discrimination with diagnosis (Leader only)
• Unclear where the funding would come from or which department(s) budgets would pay for the program a
Illustrative quote: "I think a main consideration is for follow-up... if a patient's family member ended up going in for surveillance in another system, or they don't have the same type of staff to implement it -they could get off course" (Staff) Table 4 Implementation Factors To Consider: Staff and Leader Perspectives (N=14)
Establish and standardize roles, documentation and communication workflows
• Important for all involved staff to be operating from same processes for placing and tracking orders
• Important to create effective and efficient documentation and communication methods across and within departments
Develop & build structures for electronically placing and tracking orders and related results
• Create a specific electronic LS code for specimen ordering and tracking
• Develop online, electronic consenting procedures if consent is needed
• Develop electronic means of indicating patients have opted out of screening
• Consider setting up ordering/tracking so that one department (e.g. Pathology) can order the screening while another (e.g. Genetics) can track and follow up on results
Involve key departments and related champions in the planning and decision-making
• Involve as partners: medical genetics, oncology, gastroenterology, primary care, medical informatics, senior leadership, pathology, surgery, Ob/Gyn, laboratory services, business services, and Tumor registry
• Engage stakeholders early in the process; establish clear organizational goals regarding LS screening approach
Determine laboratory for processing test -assess pros / cons for external or internal lab
In-house laboratory pros
• Possibly more sustainable /affordable in the long run due to reducing test processing and follow up errors
• Possibly more streamlined and easier to setup workflows and timely communication across/within departments
• May provide a better service to patients with streamlined communication and follow up coordination
In-house laboratory cons
• Costs to set it up/develop infrastructure still unknown and may be prohibitive
• Depending on chosen test, may have less knowledgeable and experienced staff for interpreting results/increased training needs
• May drive up costs to the organization by fostering unnecessary ordering of genetic tests
External laboratory pros
• If chosen test requires specialized expertise/knowledge may be better to use an external specialized lab
• External lab interpretation may be more accurate due to greater standardization
External laboratory cons
• Lab requirements may not integrate well with organization's approach/workflows, potentially decreasing accuracy of documentation and follow up
• Lab results may not be as timely as an internal lab
Conduct formal business case analysis to assess costs, and needed resources / staffing
• Establish where money/needed resources will come from to get the work done
• Determine costs related to chosen test, supplies and equipment, including whether utilizing an internal (e.g. infrastructure, equipment) or external lab (e.g. processing fees)
• Determine additional staffing needs for impacted departments (e.g. pathology, genetics) due to possible increases in workload
• Determine costs/staff time needed for IT support and builds in the EMR
• Determine costs related to staff training and an education/awareness campaigns for patients and staff
• Consider if dedicated staff and FTE are needed for overall monitoring of program
Establish partnerships and best practices with other organizations
• Learn from others who having implemented universal LS screening, using both external and internal labs
• Establish partnerships with organizations to help track and follow up non-health plan family members
• Develop a tumor registry to better monitor screening, and improve coordination, communication, and follow up across departments and other organizations Genet Med. Author manuscript; available in PMC 2016 May 18.
